Systemic adverse events following rituximab therapy in patients with Graves' disease

D El Fassi; Claus Henrik Nielsen; Michael Peter Junker; H C Hasselbalch; L Hegedüs

doi:10.3275/7411

Systemic adverse events following rituximab therapy in patients with Graves' disease

D El Fassi, Claus Henrik Nielsen, Michael Peter Junker, H C Hasselbalch, L Hegedüs

Afdeling for Klinisk Fysiologi og Nuklearmedicin

33 Citationer (Scopus)

Abstract

Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.

Originalsprog	Engelsk
Tidsskrift	Journal of Endocrinological Investigation
Vol/bind	34
Udgave nummer	7
Sider (fra-til)	e163-7
ISSN	0391-4097
DOI	https://doi.org/10.3275/7411
Status	Udgivet - 2011

Adgang til dokumentet

10.3275/7411

Citationsformater

@article{e7d0023c9cb347b2b2b3188b63c9d053,

title = "Systemic adverse events following rituximab therapy in patients with Graves' disease",

abstract = "Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.",

author = "{El Fassi}, D and Nielsen, {Claus Henrik} and Junker, {Michael Peter} and Hasselbalch, {H C} and L Heged{\"u}s",

year = "2011",

doi = "10.3275/7411",

language = "English",

volume = "34",

pages = "e163--7",

journal = "Journal of Endocrinological Investigation",

issn = "0391-4097",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "7",

}

TY - JOUR

T1 - Systemic adverse events following rituximab therapy in patients with Graves' disease

AU - El Fassi, D

AU - Nielsen, Claus Henrik

AU - Junker, Michael Peter

AU - Hasselbalch, H C

AU - Hegedüs, L

PY - 2011

Y1 - 2011

N2 - Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.

AB - Rituximab (RTX) therapy has shown promising results in Graves' disease (GD), with or without ophthalmopathy. We examined the occurrence of adverse events in GD patients treated with RTX.

U2 - 10.3275/7411

DO - 10.3275/7411

M3 - Journal article

C2 - 21169731

SN - 0391-4097

VL - 34

SP - e163-7

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

IS - 7

ER -

Systemic adverse events following rituximab therapy in patients with Graves' disease

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater